ArticleJournal for immunotherapy of cancer2022

PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.

Xiaolu Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.